Lista de obras - Amarendra Pegu - Dominio Público Uruguay

A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge

scientific article published on 01 September 2019

A platform incorporating trimeric antigens into self-assembling nanoparticles reveals SARS-CoV-2-spike nanoparticles to elicit substantially higher neutralizing responses than spike alone

artículo científico publicado en 2020

A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges

scientific article published on 27 April 2016

Accumulation of follicular CD8+ T cells in pathogenic SIV infection

artículo científico publicado en 2018

Activation and lysis of human CD4 cells latently infected with HIV-1

artículo científico publicado en 2015

Afferent and efferent interfaces of lymph nodes are distinguished by expression of lymphatic endothelial markers and chemokines

artículo científico publicado en 2007

Anti-HIV-1 Antibodies: An Update

scientific article published on 01 April 2020

Bispecific Antibodies Targeting Different Epitopes on the HIV-1 Envelope Exhibit Broad and Potent Neutralization.

artículo científico publicado en 2015

Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge

artículo científico publicado en 2017

Delayed vaginal SHIV infection in VRC01 and anti-α4β7 treated rhesus macaques

scientific article published on 13 May 2019

Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants

artículo científico publicado en 2021

Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants

artículo científico publicado en 2021

Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques

artículo científico publicado en 2016

Eliminating antibody polyreactivity through addition of N-linked glycosylation

artículo científico publicado en 2015

Enhanced neonatal Fc receptor function improves protection against primate SHIV infection

artículo científico publicado en 2014

Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo

artículo científico publicado en 2014

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates

artículo científico publicado en 2020

Fc-mediated effector function contributes to the in vivo antiviral effect of an HIV neutralizing antibody

artículo científico publicado en 2020

Follicular CD8 T cells accumulate in HIV infection and can kill infected cells in vitro via bispecific antibodies

artículo científico publicado en 2017

Glycoengineering HIV-1 Env creates 'supercharged' and 'hybrid' glycans to increase neutralizing antibody potency, breadth and saturation.

artículo científico publicado en 2018

Human Immunodeficiency Virus Type 1 Monoclonal Antibodies Suppress Acute Simian-Human Immunodeficiency Virus Viremia and Limit Seeding of Cell-Associated Viral Reservoirs

artículo científico publicado en 2015

Human herpesvirus 8 infects and replicates in primary cultures of activated B lymphocytes through DC-SIGN.

artículo científico publicado en 2008

Improved delivery of broadly neutralizing antibodies by nanocapsules suppresses SHIV infection in the CNS of infant rhesus macaques

scientific article published on 20 July 2021

Improvement of antibody functionality by structure-guided paratope engraftment

artículo científico publicado en 2019

Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials.

artículo científico publicado en 2018

Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor

artículo científico publicado en 2014

Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound

artículo científico publicado en 2020

New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency

artículo científico publicado en 2015

Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based Design

artículo científico publicado en 2016

P13-01. Crystal structure and function of a monoclonal antibody against primate CD4 that blocks HIV/SIV infection

artículo científico publicado en 2009

P13-07 LB. A human blocking antibody to CCR5 partially protects against lentiviral infection in non-human primates

artículo científico publicado en 2009

Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys

artículo científico publicado en 2017

Rational design and in vivo selection of SHIVs encoding transmitted/founder subtype C HIV-1 envelopes

article

Removal of variable domain N-linked glycosylation as a means to improve the homogeneity of HIV-1 broadly neutralizing antibodies

artículo científico publicado en 2020

Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial

scientific article published on 28 August 2019

Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults

artículo científico publicado en 2015

Single-dose bNAb cocktail or abbreviated ART post-exposure regimens achieve tight SHIV control without adaptive immunity

scientific article published on 07 January 2020

Surface-Matrix Screening Identifies Semi-specific Interactions that Improve Potency of a Near Pan-reactive HIV-1-Neutralizing Antibody

artículo científico publicado en 2018

Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection

artículo científico publicado en 2015

Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques

artículo científico publicado en 2017

Use of broadly neutralizing antibodies for HIV-1 prevention

artículo científico publicado en 2017

Virological Control by the CD4-Binding Site Antibody N6 in Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys

artículo científico publicado en 2017

Lista de obras de Amarendra Pegu

A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge

A platform incorporating trimeric antigens into self-assembling nanoparticles reveals SARS-CoV-2-spike nanoparticles to elicit substantially higher neutralizing responses than spike alone

A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges

Accumulation of follicular CD8+ T cells in pathogenic SIV infection

Activation and lysis of human CD4 cells latently infected with HIV-1

Afferent and efferent interfaces of lymph nodes are distinguished by expression of lymphatic endothelial markers and chemokines

Anti-HIV-1 Antibodies: An Update

Bispecific Antibodies Targeting Different Epitopes on the HIV-1 Envelope Exhibit Broad and Potent Neutralization.

Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge

Delayed vaginal SHIV infection in VRC01 and anti-α4β7 treated rhesus macaques

Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants

Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants

Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques

Eliminating antibody polyreactivity through addition of N-linked glycosylation

Enhanced neonatal Fc receptor function improves protection against primate SHIV infection

Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates

Fc-mediated effector function contributes to the in vivo antiviral effect of an HIV neutralizing antibody

Follicular CD8 T cells accumulate in HIV infection and can kill infected cells in vitro via bispecific antibodies

Glycoengineering HIV-1 Env creates 'supercharged' and 'hybrid' glycans to increase neutralizing antibody potency, breadth and saturation.

Human Immunodeficiency Virus Type 1 Monoclonal Antibodies Suppress Acute Simian-Human Immunodeficiency Virus Viremia and Limit Seeding of Cell-Associated Viral Reservoirs

Human herpesvirus 8 infects and replicates in primary cultures of activated B lymphocytes through DC-SIGN.

Improved delivery of broadly neutralizing antibodies by nanocapsules suppresses SHIV infection in the CNS of infant rhesus macaques

Improvement of antibody functionality by structure-guided paratope engraftment

Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials.

Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor

Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound

New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency

Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based Design

P13-01. Crystal structure and function of a monoclonal antibody against primate CD4 that blocks HIV/SIV infection

P13-07 LB. A human blocking antibody to CCR5 partially protects against lentiviral infection in non-human primates

Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys

Rational design and in vivo selection of SHIVs encoding transmitted/founder subtype C HIV-1 envelopes

Removal of variable domain N-linked glycosylation as a means to improve the homogeneity of HIV-1 broadly neutralizing antibodies

Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial

Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults

Single-dose bNAb cocktail or abbreviated ART post-exposure regimens achieve tight SHIV control without adaptive immunity

Surface-Matrix Screening Identifies Semi-specific Interactions that Improve Potency of a Near Pan-reactive HIV-1-Neutralizing Antibody

Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection

Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques

Use of broadly neutralizing antibodies for HIV-1 prevention

Virological Control by the CD4-Binding Site Antibody N6 in Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys